Untitled

2. Mission Statement

To accelerate next-generation longevity research by developing rapid-proof, low-capex cellular-rejuvenation programs—transforming early-stage biology into licensable therapeutic IP.

3. Founding Team

Dr. Siamak Tabibzadeh

Chief Scientific Officer
World authority on cellular senescence; founder of Frontiers in BioScience, inventor of patents valued >$100 M.

Joshua Tabibzadeh

Chief Executive Officer
Biotech strategy & operations, IP development, commercialization

Aaron Tabibzadeh MD

Head of Research, CEO

Advisory Board (to be filled): Experts in peptide engineering, gene therapy, longevity venture capital

4. Scientific Heritage

The company builds upon our pioneering research in cellular senescence and molecular aging—patents independently valued above $100 million.
While those patents remain separate assets, they provide scientific credibility and a springboard for Regenerative BioSciences’ new R&D pipeline.

5. Problem & Opportunity

Aging and degeneration drive > 60 % of global healthcare costs.
Longevity market: projected >$610 B by 2030.
Yet most gene or cell therapies require >$50 M to reach proof-of-concept.

Gap: efficient, cross-disciplinary programs that generate licensable IP within 12 months at <$100 K per asset.

6. Our Solution — Fast-Proof Biotech Platform

We identify and validate low-cost, high-value biological targets in aging and regeneration, using peptide and gene-modulation approaches with rapid cell-based assays and CRO partnerships for speed.

Ten priority programs from the research report:

Mitochondrial repair analogs (SS-31 family)
Hair-follicle reactivation complex
Autophagy “on-demand” peptide
Anti-fibrotic micropeptide
Gut-barrier repair peptide
Senolytic peptide (FOXO4-p53 analog 2.0)
Brown-fat activator
Vascular glycocalyx regenerator
Hair-loss gene modulation platform
Eye-color lightening therapy

Each program has a clear 6-to-9 month proof path and sub-$100 K budget.

7. Pipeline Snapshot

Tier 1 – Rejuvenation	Mitochondrial, Autophagy, Senolytic
Tier 2 – Regeneration	Fibrosis, Gut Barrier, Vascular
Tier 3 – Cosmetic BioTech	Hair, Eye, Skin

Goal: 10 provisionals filed within 18 months → portfolio valuation $50–100 M based on comparables.

8. Go-to-Market Strategy

Proof → Patent → Partner: Demonstrate ≥ 30 % cellular effect → file provisional → license to biotech or cosmetic partner.

Lean CRO Model: External assays for cost efficiency ($25–50 K per asset).
Revenue Path: Licensing fees, milestones, and R&D grants (SBIR, DoD, NIH).

9. Funding Ask & Use of Proceeds ($3 M Seed)

Allocation	%	Use
Scientific Team (8 PhDs + 2 consultants)	35 %	Core R&D execution
CRO & Materials	30 %	Assay packages, peptide synthesis & analytics
IP & Legal	15 %	Provisional filings (8 per quarter) + FTO reviews
Operations & Facilities	10 %	Lab setup / equipment lease
Administrative Salary (Joshua Tabibzadeh)	7 %	CEO salary <$80K base + $40K incentive
Grant Matching & BD Budget	10 %	SBIR co-funding + partnership outreach

Total Budget: ≈ $2,990,000 USD
Runway: 18 months (~$166K burn/month)

10. Milestones

Quarter	Milestone
Q1–Q2 (0–6 mo)	Hire core PhDs, launch first five assays (mito, senolytic, fibrosis, hair, gut)
Q3 (6–9 mo)	Initial PoC data ≥ 30 % improvement → first 3 provisionals
Q4 (9–12 mo)	SBIR submission & industry presentations
Q5–Q6 (12–18 mo)	Licensing negotiations / Series A bridge round

With even two validated PoC assets, Regenerative BioSciences targets $40–60 M valuation within 18 months.

Contact

We bridge pioneering science and rapid execution to unlock the next era of cellular rejuvenation.
Contact: joshua@senescence-labs.com